FENS Forum 2024
ESGCT 2024
CNS Therapeutics
ACT 2024
Neuroscience 2024
NLS Days 2024
Eurotox 2024
With over 40 years of experience Scantox has a long track record of successfully conducting toxicology studies. Toxicology is one of our core competencies, and at Scantox you are in direct contact with a team of experts, highly experienced in evaluating short- and long-term toxicity studies performed in most species commonly used in preclinical toxicity testing. Visit Scantox at Eurotox in September to learn more. We look forward to welcoming you onto booth 52 at the event which this time takes place in Ljubljana.
Neuro4D 2024
How are today’s neuroscience innovations shaping the future of treatment for neurodegenerative diseases? Scantox Neuro is excited to discuss this question at the upcoming Neuro4D conference in Mainz on May 27-28, 2024. This exclusive event unites key industry researchers and opinion leaders. They will discuss the latest advancements in neuroscience. The meeting will focus on disorders such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS), and Huntington’s disease. With around 60-65 attendees, the conference aims to promote highly interactive discussions.
Scantox Neuro’s Contributions to the Conference
As a sponsor of the event and thanks to an invitation from an esteemed client, Scantox Neuro is proud to share our latest research in the field of ALS. Roland Rabl and Stefanie Krassnig will highlight aspects of our in vivo and in vitro research through a talk and a poster presentation. Roland Rabl’s Talk: “Longitudinal characterization of a transgenic B6.SOD1-G93A mutant-based ALS mouse model” Key Insights:- The model is more suitable for studying early-stage ALS pathology and extends the window for therapeutic intervention
- Longitudinal tracking of NF-L and CMAP biomarkers in plasma samples enables a more sensitive approach in treatment efficacy studies
- Histological findings reveal spinal cord disease progression, including changes in TDP-43 expression, inflammation, and neuronal loss, which mirrors human ALS pathology
- Findings underscore the translational value of in vitro models in screening novel compounds targeting TDP-43 pathologies.
- They also highlight the capability of in vitro models to provide deeper insights into the molecular mechanisms behind neurodegenerative diseases
Join Us in Advancing Neuroscience
We’re looking forward to engaging with researchers at Neuro4D. This conference is a fantastic opportunity to exchange knowledge, discuss new assays and disease models, and potentially establish new partnerships. Meet with Roland and Stefanie. Learn more about their research and explore future collaborations!MRF Minipig Research Forum 2024
Are you interested to learn more about the different techniques of collecting ECG data and use of infusion systems? Then join us at the upcoming Minipig Research Forum in Amsterdam (22-24 May), where we are hosting a session on the topic. Jacketed External Telemetry, Implantable Telemetry and Snapshot ECG are different ways of collecting of cardiovascular data in general toxicology and safety pharmacology studies. These can all be collected from the Göttingen Minipig, and in the session you will be introduced to different practical approaches as well as get expert insights into administration via infusion systems using different pumps and sites of administration in the minipig. The Scantox team is available during the full MRF event, so don’t hesitate to reach out!
AngloNordic 2024
Scantox looks forward to attend the Anglo Nordic Life Science event in London again in 2024!
Over the past year, Scantox has been working intentionally to round out our service offerings, striving to become a complete, full-service IND-enabling tox lab. While our capabilities encompass many areas, we are particularly proud of our expertise in safety assessment, general toxicology, and specialty areas. Additionally, Scantox’s commitment to quality and innovation has propelled our growth and reputation within the industry. Through strategic investments in state-of-the-art facilities, the latest technology, and highly skilled scientific personnel, Scantox has positioned itself as a trusted partner for drug development and regulatory submissions. Our dedication to staying abreast of evolving regulatory requirements and industry standards further solidifies our standing as a premier CRO.
